Omthera Stockholders Approve Acquisition by AstraZeneca

           Omthera Stockholders Approve Acquisition by AstraZeneca

PR Newswire

PRINCETON, N.J., July 16, 2013

PRINCETON, N.J., July 16, 2013 /PRNewswire/ -- The stockholders of Omthera
Pharmaceuticals, Inc. (NASDAQ: OMTH) (the "Company") voted today at a special
meeting of stockholders to adopt the previously announced merger agreement
providing for the acquisition of the Company by an affiliate of AstraZeneca
PLC. The votes cast by the Company's stockholders in favor of the proposal to
adopt the merger agreement represented approximately 88.3 percent of the
Company's issued and outstanding common stock entitled to vote as of June 13,
2013, the record date for the special meeting.

(Logo: http://photos.prnewswire.com/prnh/20130528/NY21129LOGO-a)

The receipt of the approval of the Company's stockholders of the proposal to
adopt the merger agreement satisfies one of the conditions to consummation of
the proposed merger. The consummation of the merger remains subject to
certain other closing conditions set forth in the merger agreement.

About Omthera Pharmaceuticals, Inc.

Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company
focused on the development and commercialization of new therapies for
dyslipidemia and the treatment of cardiovascular disease. Epanova™, currently
the Company's sole product candidate, is a late-stage, novel, omega-3 free
fatty acid composition that meaningfully reduces triglycerides, improves other
key lipid parameters and is expected to increase patient convenience with
2-gram once-a-day dosing with or without meals. Epanova™ is a coated soft
gelatin capsule containing a complex mixture of polyunsaturated free fatty
acids derived from fish oils, including multiple long-chain omega-3 and
omega-6 fatty acids, with EPA, DHA, and docosapentaenoic acid being the most
abundant forms of omega-3 fatty acids. The Company has completed
pharmacokinetic and Phase III clinical studies to investigate the safety and
efficacy profile of Epanova™. In 2012 the Company reported positive results
from its Phase III EVOLVE and ESPRIT trials, both of which were conducted
under SPA agreements with the U.S. Food and Drug Administration. Omthera holds
worldwide rights to Epanova™ under a license from Chrysalis Pharma AG, a
privately held Swiss company that is the owner of the product. For more
information, please visit http://www.omthera.com.

Safe Harbor for Forward-Looking Statements

This press release, in particular statements regarding the proposed
transaction between an affiliate of AstraZeneca PLC and the Company, the
expected timetable for completing the transaction, future financial and
operating results, benefits and synergies of the transaction, future
opportunities for the combined company and any other statements about
AstraZeneca PLC or Company managements' future expectations, beliefs, goals,
plans or prospects, includes forward-looking statements that are based on
certain beliefs and assumptions and reflect the current expectations of the
Company, AstraZeneca PLC and their respective management. Statements that are
predictive in nature, that depend on or relate to future events or conditions,
or that include words such as "believes," "anticipates," "expects,"
"continues," "predict," "potential," "contemplates," "may," "will," "likely,"
"could," "should," "estimates," "intends," "plans" and other similar
expressions are forward-looking statements. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. Forward-looking statements involve known and
unknown risks, assumptions and uncertainties that may cause actual results in
future periods to differ materially from those projected or contemplated in
the forward-looking statements, and you should not place undue reliance on
these statements. Some of the factors that could cause actual results to
differ materially from current expectations are: the ability to consummate the
proposed transaction; any conditions imposed on the parties in connection with
the consummation of the proposed transaction; the ability to obtain regulatory
approvals of the proposed transaction; the occurrence of any event, change or
other circumstances that could give rise to the termination of the agreement
relating to the proposed transaction; the Company's ability to maintain
relationships with employees and third parties following announcement of the
proposed transaction; the ability of the parties to satisfy the conditions to
the closing of the proposed transaction; the risk that the proposed
transaction may not be completed in the time frame expected by the parties or
at all; and the risks that are described from time to time in the Company's
reports filed with the SEC, including the Prospectus, in other of the
Company's filings with the SEC from time to time, including Quarterly Reports
on Form 10-Q and Current Reports on Form 8-K, and on general industry and
economic conditions. If the proposed transaction is consummated, our
stockholders will cease to have any equity interest in the Company and will
have no right to participate in its earnings and future growth. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

NY: 800258-3

Omthera Contact:
Christian Schade
Executive Vice President & Chief Financial Officer
Omthera Pharmaceuticals, Inc.
T: 908-741-4399
E: info@Omthera.com 

SOURCE Omthera Pharmaceuticals, Inc.

Website: http://www.omthera.com
 
Press spacebar to pause and continue. Press esc to stop.